Free Trial
OTCMKTS:EVTCY

Evotec (EVTCY) Stock Price, News & Analysis

Evotec logo
$4.29 +0.06 (+1.42%)
As of 05/2/2025

About Evotec Stock (OTCMKTS:EVTCY)

Key Stats

Today's Range
$4.27
$4.38
50-Day Range
$2.97
$4.39
52-Week Range
$14.22
$26.57
Volume
55,744 shs
Average Volume
2,407 shs
Market Capitalization
$1.42 billion
P/E Ratio
10.46
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVTCY Stock News Headlines

Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
See More Headlines

EVTCY Stock Analysis - Frequently Asked Questions

Evotec's stock was trading at $4.16 on January 1st, 2025. Since then, EVTCY stock has increased by 3.1% and is now trading at $4.29.
View the best growth stocks for 2025 here
.

Evotec shares split on Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly created shares were distributed to shareholders after the market closes on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

Evotec subsidiaries include these companies: Central Glass Germany. GmbH, Central Glass Germany, Rigenerand Srl, GlaxoSmithKine's the Verona site, Just-Evotec Biologics, Aptuit, Cyprotex, and others.

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
5/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:EVTCY
Employees
4,200
Year Founded
1993

Profitability

Trailing P/E Ratio
10.46
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$7.14 million
Pretax Margin
23.90%

Debt

Sales & Book Value

Annual Sales
$572.16 million
Cash Flow
$0.04 per share
Price / Cash Flow
105.53
Book Value
$2.52 per share
Price / Book
1.70

Miscellaneous

Free Float
N/A
Market Cap
$1.42 billion
Optionable
Not Optionable
Beta
0.98

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (OTCMKTS:EVTCY) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners